RT Journal Article
SR Electronic
T1 Response to Measles-Mumps-Rubella Vaccine in Children with Autism Spectrum Disorders
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 377
OP 382
VO 27
IS 3
A1 GENTILE, IVAN
A1 BRAVACCIO, CARMELA
A1 BONAVOLTA, RAFFAELE
A1 ZAPPULO, EMANUELA
A1 SCARICA, SABRINA
A1 RICCIO, MARIA PIA
A1 SETTIMI, ALESSANDRO
A1 PORTELLA, GIUSEPPE
A1 PASCOTTO, ANTONIO
A1 BORGIA, GUGLIELMO
YR 2013
UL http://iv.iiarjournals.org/content/27/3/377.abstract
AB Background/Aim: The etiology of autism spectrum disorders (ASD) is unknown. The measles-mumps-rubella (MMR) vaccination has been in the past implicated in ASD pathogenesis. The aim of our study was to evaluate the rate of seropositivity and the levels of antibodies against MMR antigens in a cohort of children with ASD compared to control children. Patients and Methods: In a cohort of children with ASD and same-age healthy controls, we measured levels and seropositivity of antibodies against MMR. Results: A total of 60 children, 31 with ASD and 29 controls were enrolled. The seropositivity rate and levels of all the three antibodies were similar in cases and controls. Conclusion: Children with ASD have a similar level and seropositivity rate of antibodies against the MMR vaccine to same-age controls. As persistent infections are typically associated with high antibody levels, our results support the arguments against a role of MMR vaccination as a causal factor or co-factor in development of ASD.